Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Clinical Development
Brought to you by:
Biotech
Biohaven bounces back with phase 3 ultra-rare disease win
Biohaven linked troriluzole to a slowing of progression, setting it up to take another shot at approval with an asset that the FDA refused to review.
Nick Paul Taylor
Sep 23, 2024 9:22am
ESMO: Innovent links cytokine to colorectal cancer responses
Sep 18, 2024 9:53am
Sponsored
Market Insights: What’s Driving the Shift Toward FSP Models in Clinical Development?
Oct 2, 2024 8:00am
Ascendis' dwarfism drug hits in phase 3, threatens BioMarin
Sep 17, 2024 9:36am
Merck, Daiichi ADC hits goal in phase 3 lung cancer study
Sep 17, 2024 7:13am
Boehringer's phase 3 lung fibrosis trial hits primary endpoint
Sep 16, 2024 8:30am